Acute Myelocytic Leukemia (AML) - Pipeline Review, Q1 2011

Date: February 1, 2011
Pages: 365
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: AA56F7D769AEN
Leaflet:

Download PDF Leaflet

Acute Myelocytic Leukemia (AML) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Acute Myelocytic Leukemia (AML) - Pipeline Review, Q1 2011', provides an overview of the Acute Myelocytic Leukemia therapeutic pipeline. This report provides information on the therapeutic development for Acute Myelocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia. 'Acute Myelocytic Leukemia (AML) - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Acute Myelocytic Leukemia.
  • A review of the Acute Myelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Acute Myelocytic Leukemia pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia pipeline depth and focus of Acute Myelocytic Leukemia therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Myelocytic Leukemia (AML) Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Myelocytic Leukemia (AML)
Acute Myelocytic Leukemia (AML) Therapeutics under Development by Companies
Acute Myelocytic Leukemia (AML) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Acute Myelocytic Leukemia (AML) Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Seattle Genetics, Inc.
medac GmbH
Merck & Co., Inc.
Micromet, Inc.
Generex Biotechnology Corporation
Takeda Pharmaceutical Company Limited
Bio-Path Holdings, Inc.
BioSante Pharmaceuticals, Inc.
Novartis AG
Cephalon, Inc.
Eisai Co., Ltd.
Genta Incorporated
Sunesis Pharmaceuticals, Inc.
SuperGen, Inc.
Exelixis, Inc.
Astex Therapeutics Limited
Cyclacel Pharmaceuticals Inc.
Vion Pharmaceuticals, Inc.
Celgene Corporation
Geron Corporation
Merck KGaA
Access Pharmaceuticals, Inc.
EntreMed, Inc.
EpiCept Corporation
Ariad Pharmaceuticals, Inc.
Lorus Therapeutics Inc
MethylGene Inc
Callisto Pharmaceuticals, Inc.
ChemGenex Pharmaceuticals Limited
OXiGENE, Inc.
Critical Outcome Technologies Inc.
CSL Limited
TopoTarget A/S
CytRx Corporation
Pharmacyclics, Inc.
Lipoxen PLC
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Sareum Holdings plc
Clavis Pharma ASA
Innate Pharma SA
Baylor College of Medicine
Debiopharm Group
Chroma Therapeutics Ltd.
Avaris
Actinium Pharmaceuticals, Inc.
BioMAS Ltd.
Calistoga Pharmaceuticals, Inc.
Aegera Therapeutics Inc.
Celator Pharmaceuticals, Inc.
Altor BioScience Corporation
Coronado Biosciences, Inc.
Eleos Inc.
Arno Therapeutics, Inc.
S*BIO Pte Ltd
Stemline Therapeutics, Inc.
Proacta, Inc.
Onconova Therapeutics, Inc
Gemin X Pharmaceuticals
Esperance Pharmaceuticals, Inc.
Quatrx Pharmaceutical Company
KaloBios Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc.
SymbioTec GmbH
AstraZeneca AB
Kanisa Pharmaceuticals, Inc.
Targa Therapeutics Corp.
Sentinel Oncology Limited
The Vaccine Company L.P.
Universities/Institutes Involved in Acute Myelocytic Leukemia (AML) Therapeutics Development
Acute Myelocytic Leukemia (AML) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Aldesleukin + Maxamine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Aracytine + Daunorubicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
AZACITIDINE (VIDAZA) - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
CEP-701 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Ceplene - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Clolar + Cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
CYTARABINE - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Etoposide + Mitoxantrone + Lintuzumab - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Dacogen - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Daunorubicin + Cytarabine + Mylotarg - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
ELACYT - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
GM-CSF - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
GVAX Immunotherapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mylotarg + Daunorubicin + Cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PR1 Leukemia Peptide Vaccine + Incomplete Freund's Adjuvant + GM-CSF - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PR1 Leukemia Peptide Vaccine + Sargramostim - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Proleukin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Treosulfan + Busulfan - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Treosulfan + Fludarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Trisenox + Cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vesanoid (ATRA) - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vesanoid (ATRA) + AZACITIDINE (VIDAZA) - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vesanoid(ATRA) + CYTARABINE - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vidaza - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vosaroxin + Cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Late Stage Drug Profiles – Universities/Institutes
5-AZACYTIDIN - DRUG PROFILE
  Product Description
  Mechanism of Action
  R&D Progress
Aldesleukin + Filgrastim + Asparaginase + Busulfan + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Fludarabine Phosphate + Idarubicin + Methotrexate + Therapeutic Hydrocortisone + Thioguanine + Allogeneic Bone Marrow Transplantation + Radiation Therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Aldesleukin + Filgrastim + Busulfan + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Etoposide + Autologous Bone Marrow Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Aldesleukin + Filgrastim + Cyclophosphamide + Cytarabine + Etoposide + Idarubicin + Melphalan + Peripheral blood stem cell transplantation + Radiation therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
alemtuzumab + arsenic trioxide + azacitidine + busulfan + clofarabine + cytarabine + daunorubicin hydrochloride + fludarabine phosphate + gemtuzumab ozogamicin + melphalan + tipifarnib - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
all-trans retinoid acid + idarubicin + mitoxantrone + daunorubicin + cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
amsacrine + asparaginase + cytarabine + daunorubicin hydrochloride + etoposide + methotrexate + mitoxantrone hydrochloride + therapeutic hydrocortisone + allogeneic bone marrow transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Amsacrine + Carmustine + Cytarabine + Etoposide + Idarubicin + Mitoxantrone Hydrochloride + Peripheral Blood Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Anthracyclines + liposomal daunorubicin + 2-CDA + AI - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Anti-thymocyte globulin + Cyclophosphamide + Cytarabine + Methylprednisolone + Thiotepa - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Asparaginase + Cytarabine + Daunorubicin + Etoposide + Thioguanine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Asparaginase + Cytarabine + Daunorubicin Hydrochloride + Etoposide + Gemtuzumab Ozogamicin + Mitoxantrone Hydrochloride - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
ATRA - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Busulfan + Cyclophosphamide + Autologous Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Busulfan + Cyclophosphamide + Melphalan + Allogeneic Hematopoietic Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Busulfan + Fludarabine + Cyclophosphamide + Radiation Therapy + Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Busulfan + Radiation Therapy + Peripheral Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Campath - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cerubidine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cladribine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cladribine + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
clofarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cyclophosphamide + Cyclosporine + Methotrexate + Stem Cell Transplantation + Radiation Therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cyclosporin + Methylprednisolone + Umbilical Cord Blood Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Daunorubicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
cytarabine + daunorubicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Daunorubicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Daunorubicin + Etoposide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Daunorubicin + Etoposide + Filgrastim - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
cytarabine + daunorubicin + etoposide + hydroxyurea + idarubicin + mitoxantrone + thioguanine + tretinoin + valspodar - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Daunorubicin + Gemtuzumab - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Daunorubicin + Gemtuzumab Ozogamicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Daunorubicin + Mylotarg + Filgrastim/Sargramostim - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Daunorubicin + Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Daunorubicin + Zosuquidar Trihydrochloride - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
cytarabine + daunorubicin hydrochloride + dexamethasone + etoposide + idarubicin + mitoxantrone hydrochloride + thioguanine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Daunorubicin hydrochloride + Etoposide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
cytarabine + daunorubicin hydrochloride + midostaurin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
cytarabine + etoposide + idarubicin + mitoxantrone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Etoposide + Idarubicin + Mitoxantrone Hydrochloride + Gemtuzumab Ozogamicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Gemtuzumab Ozogamicin + Sargramostim - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Idarubicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Idarubicin + All-trans retinoic acid + Mitoxantrone + Etoposid - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Idarubicin + Etoposide + All-trans retinoic acid + Pegfilgrastim - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Idarubicin + Etoposide + ATRA + Pegfilgrastim - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Idarubicin + Etoposide + Pegfilgrastim - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Idarubicin + Mitoxantrone + All-trans-Retinoic Acid + Etoposide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Thioguanine + Daunorubicin + Cyclophosphamide + G-CSF - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine + Thioguanine + Daunorubicin + Cyclophosphamide + G-CSF + stem cell transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine+ Idarubicin +Etoposide+ All-trans retinoic acid+ Pegfilgrastim - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine+ Idarubicin +Etoposide+ Fludarabine +G-CSF - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytarabine+ Idarubicin All-trans retinoic acid+ Mitoxantrone+ Etoposide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
cytosine arabinoside - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cytosine Arabinoside + Idarubicin + Etoposide + Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Daunorubicin + Chemotherapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Daunorubicin + Cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Daunorubicin + Cytarabine + Etoposide + Cyclophosphamide + Busulfan + Interleukin-2 + PBSCT - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Daunorubicin + Cytarabine + Midostaurin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
DAUNORUBICINE + CYTARABINE - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
DaunoXome - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Daunoxome - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
decitabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Enocitabine + Daunorubicin + Mercaptopurine + Mitoxantrone + Etoposide + Vindesine + Aclarubicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Filgrastim + Amsacrine + Carmustine + Cytarabine + Etoposide + Idarubicin + Mitoxantrone Hydrochloride + Peripheral Blood Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
filgrastim + amsacrine + cyclophosphamide + cytarabine + daunorubicin hydrochloride + etoposide + idarubicin + mitoxantrone hydrochloride + thioguanine + tretinoin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
filgrastim + amsacrine + cyclophosphamide + cytarabine + daunorubicin hydrochloride + etoposide + idarubicin + mitoxantrone hydrochloride + thioguanine + tretinoin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Filgrastim + Busulfan + Cyclophosphamide + Cytarabine + Daunorubicin hydrochloride + Etoposide + Idarubicin + Mesna + Mitoxantrone hydrochloride + Stem cell transplantation + Radiation therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
filgrastim + cytarabine + daunorubicin hydrochloride + etoposide + fludarabine phosphate + tretinoin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
filgrastim + cytarabine + daunorubicin hydrochloride + etoposide + fludarabine phosphate + tretinoin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Filgrastim + Sargramostim + Busulfan + Cyclophosphamide + Gemtuzumab Ozogamicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Filgrastim + Sargramostim + Cytarabine + Daunorubicin Hydrochloride + Gemtuzumab ozogamicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Filgrastim + Sargramostim + Cytarabine + Daunorubicin Hydrochloride + Gemtuzumab ozogamicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Fludarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Fludarabine + Busulfan + Campath-1H - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Fludarabine + Cytarabine + DaunoXome + Etoposide + Thioguanine + Cyclophosphamide + Busulfan + Melphalan - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Fludarabine + Cytarabine + Filgrastim - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Fludarabine + Cytarabine + Idarubicin + Mylotarg - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
G-CSF - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Gemtuzumab ozogamicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Gemtuzumab Ozogamicin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Hematopoietic Cell Transplantation + Total Body Irradiation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Idarubicin + Chemotherapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Idarubicin + Cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Idarubicin + Cytarabine + Daunorubicin hydrochloride + Dexamethasone + Etoposide + Thioguanine + Radiation therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Idarubicin + Cytarabine + Lomustine + Methotrexate + 6-Mercaptopurine + Norethandrolone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Idarubicin + Cytarabine + Thioguanine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Idarubicin + Etoposide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
liposomal daunorubicin + fludarabine + ara-C + G-CSF - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Lomustine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mercaptopurine + Methotrexate + Tretinoin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mitoxantrone hydrochloride + Cytarabine + Daunorubicin hydrochloride + Dexamethasone + Etoposide + Thioguanine + Radiation therapy - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mitoxantrone Hydrochloride + Etoposide + Cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mylotarg - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mylotarg + Daunorubicin + Cytarabine + Mitoxantrone + Stem Cell Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mylotarg + Idarubicin + Etoposide + Cytarabine + ATRA + Pegfilgrastim - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
oblimersen sodium + cytarabine + daunorubicin hydrochloride - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Procrit - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PSC-833 + Cytarabine + Daunorubicin hydrochloride + Etoposide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Recombinant flt3 ligand - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Thiotepa + Cyclophosphamide + ATG + OKT3 + Rituximab + Radiation therapy + Stem cell tranplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Thymoglobulin for Cancer - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Tipifarnib - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Tretinoin + Cytarabine + Daunorubicin + Arsenic Trioxide + Mercaptopurine + Methotrexate - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Tretinoin + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Tretinoin + Idarubicin + Mitoxantrone Hydrochloride + Mercaptopurine + Methotrexate - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Tretinoin + Idraubicin + cytarabine + Mitoxantrone + Etoposide + Allogenic Bone Marrow Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Trisenox + Cytarabine + Idarubicin + Mercaptopurine + Methotrexate + Mitoxantrone hydrochloride + Tretinoin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Umbilical Cord Blood Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vidaza - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vidaza - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Zosuquidar Trihydrochloride + Daunorubicin + Cytarabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Discontinued Products
Acute Myelocytic Leukemia (AML) - Featured News
1. DEC 21, 2010: EPICEPT WINS ISRAELI APPROVAL FOR CEPLENE
2. DEC 21, 2010: SUNESIS BEGINS PHASE III TRIAL OF VOSAROXIN IN ACUTE MYELOID LEUKEMIA
3. DEC 07, 2010: CELATOR REPORTS POSITIVE PHASE II STUDY DATA ON CPX-351 IN ACUTE MYELOID LEUKEMIA
4. DEC 07, 2010: CELGENE ANNOUNCES STUDY RESULTS OF REVLIMID ON RISK OF PROGRESSION TO ACUTE MYELOID LEUKAEMIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
5. DEC 06, 2010: ASCENTA AND LEUKEMIA & LYMPHOMA SOCIETY SIGN AGREEMENT TO DEVELOP AT-406
6. DEC 06, 2010: GERON PRESENTS CLINICAL DATA ON TELOMERASE VACCINE AT 2010 AMERICAN SOCIETY OF HEMATOLOGY MEETING
7. DEC 06, 2010: MILLENNIUM REPORTS ENCOURAGING PHASE I RESULTS OF MLN4924 IN ACUTE MYELOID LEUKEMIA
8. DEC 05, 2010: EPICEPT ANNOUNCES CEPLENE POSTER PRESENTATION AT ANNUAL MEETING OF AMERICAN SOCIETY OF HEMATOLOGY
9. DEC 03, 2010: LIGAND ANNOUNCES PRESENTATION OF DATA FROM MULTIPLE STUDIES OF DINACICLIB BY MERCK AT ASH ANNUAL MEETING
10. DEC 03, 2010: SUPERGEN TO PRESENT SGI-110 PRECLINICAL DATA AT ASH ANNUAL MEETING
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 365

LIST OF TABLES

Number of Products Under Development for Acute Myelocytic Leukemia (AML), 2011
Products under Development for Acute Myelocytic Leukemia (AML) – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Bristol-Myers Squibb Company, 2011
Genzyme Corporation, 2011
Johnson & Johnson, 2011
Boehringer Ingelheim GmbH, 2011
F. Hoffmann-La Roche Ltd., 2011
Sanofi-Aventis, 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
Seattle Genetics, Inc., 2011
medac GmbH, 2011
Merck & Co., Inc., 2011
Micromet, Inc., 2011
Generex Biotechnology Corporation, 2011
Takeda Pharmaceutical Company Limited, 2011
Bio-Path Holdings, Inc., 2011
BioSante Pharmaceuticals, Inc., 2011
Novartis AG, 2011
Cephalon, Inc., 2011
Eisai Co., Ltd., 2011
Genta Incorporated, 2011
Sunesis Pharmaceuticals, Inc., 2011
SuperGen, Inc., 2011
Exelixis, Inc., 2011
Astex Therapeutics Limited, 2011
Cyclacel Pharmaceuticals Inc., 2011
Vion Pharmaceuticals, Inc., 2011
Celgene Corporation, 2011
Geron Corporation, 2011
Merck KGaA, 2011
Access Pharmaceuticals, Inc., 2011
EntreMed, Inc., 2011
EpiCept Corporation, 2011
Ariad Pharmaceuticals, Inc., 2011
Lorus Therapeutics Inc, 2011
MethylGene Inc, 2011
Callisto Pharmaceuticals, Inc., 2011
ChemGenex Pharmaceuticals Limited, 2011
OXiGENE, Inc., 2011
Critical Outcome Technologies Inc., 2011
CSL Limited, 2011
TopoTarget A/S, 2011
CytRx Corporation, 2011
Pharmacyclics, Inc., 2011
Lipoxen PLC, 2011
Threshold Pharmaceuticals, Inc., 2011
Synta Pharmaceuticals Corp., 2011
Sareum Holdings plc, 2011
Clavis Pharma ASA, 2011
Innate Pharma SA, 2011
Baylor College of Medicine, 2011
Debiopharm Group, 2011
Chroma Therapeutics Ltd., 2011
Avaris, 2011
Actinium Pharmaceuticals, Inc., 2011
BioMAS Ltd., 2011
Calistoga Pharmaceuticals, Inc., 2011
Aegera Therapeutics Inc., 2011
Celator Pharmaceuticals, Inc., 2011
Altor BioScience Corporation, 2011
Coronado Biosciences, Inc., 2011
Eleos Inc., 2011
Arno Therapeutics, Inc., 2011
S*BIO Pte Ltd, 2011
Stemline Therapeutics, Inc., 2011
Proacta, Inc., 2011
Onconova Therapeutics, Inc, 2011
Gemin X Pharmaceuticals, 2011
Esperance Pharmaceuticals, Inc., 2011
Quatrx Pharmaceutical Company, 2011
KaloBios Pharmaceuticals, Inc., 2011
Cylene Pharmaceuticals, Inc., 2011
SymbioTec GmbH, 2011
AstraZeneca AB, 2011
Kanisa Pharmaceuticals, Inc., 2011
Targa Therapeutics Corp., 2011
Sentinel Oncology Limited, 2011
The Vaccine Company L.P., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products 356

LIST OF FIGURES

Number of Products under Development for Acute Myelocytic Leukemia (AML), 2011
Products under Development for Acute Myelocytic Leukemia (AML) – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011 135

Ask Your Question

Acute Myelocytic Leukemia (AML) - Pipeline Review, Q1 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: